Cardiovascular disease

How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic. Those with obesity drugs already on the market...

Novo Nordisk’s (NYSE:NVO) popular semaglutide drugs, Wegovy and Ozempic, may unlock three potential new markets, potentially boosting the company’s fortunes, The Motley Fool reported. Over the past year, Novo Nordisk‘s shares have surged 79%, largely due to the success of its...

Pfizer Inc (NYSE: PFE) has provided an update on the Phase 2b study of vupanorsen, investigational antisense therapy for cardiovascular (CV) risk reduction and severe hypertriglyceridemia. In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met...

Milestone Pharmaceuticals Inc (NASDAQ: MIST) hit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint. A year later, it’s touting new data on its secondary endpoints and a partnership...

Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF). Data were presented at the American College of Cardiology’s Annual...

Novartis AG (NYSE: NVS) revealed details on Phase 3 PARADISE-MI trial evaluating Entresto (sacubitril/valsartan) compared with ramipril in a contemporary acute myocardial infarction (AMI) population. Data were presented at the American College of Cardiology's virtual...

Most heart disease drugs are aimed at reducing the "bad" low-density lipoprotein (LDL) cholesterol. However, strategies related to cutting LDL cholesterol and increasing high-density lipoprotein (HDL) cholesterol are of interest in combating the risk of heart disease. HDL cholesterol is...

The FDA has signed off conditional approval for the STAR-T study to assess CytoSorbents Corporation's (NASDAQ: CTSO) blood purification device, CytoSorb, to remove Ticagrelor. The company can now initiate clinical trial agreement negotiations and institutional review...

Amarin Corporation (NASDAQ: AMRN) presented data for its cardiovascular outcome study of its prescription Vascepa (icosapent ethyl), the REDUCE-IT study. Vascepa demonstrated a statistically significant 30 percent risk reduction in cardiovascular events compared to placebo in the statin-treated...